Date Range
Date Range
Date Range
Gems Publishing USA
Tom Orent
12 Walnut Street
Framingham, Massachusetts, 01702
United States
Advanced Web Systems, LLC
Greg Rahall
315 W. Maple Ave
Fayettevfille, West Virginia, 25840
United States
Insiders Circle International is a group of investors, marketing strategists, management experts and financial wizards. We invest our time, expertise and money in exchange for equity in business. We are looking to partner with business professionals, business owners and investors who may be interested in buying selling or growing businesses.
Walk into a Bar The Rest is History. Chicago Thin Crust With A Deep Dish Attitude. Eat and Drink Until the cows come home. Beers and Cheers Hoppiness on Tap. Conversation Starters Crafted With Love. Holy Shhh-ocolate Triple Chocolate Brownie Sundae. Leave Room for the Finale. It all began when Ike Sewell imagined a pizza unlike any other. Fresh dough with a tall edge, topped with homemade sauce and more cheese than you could believe. People have been lining up ever since.
The conference provides great forum for discussion and continued dialogue around many prescient issues that continue to face our industry. James Evan-Cook, IPS Search. Attendance at this event is essential for anyone who wants to stay current on developments in the property and casualty insurance world. Convene, 237 Park Avenue, New York, NY 1001. 190 delegates from over 100 companies.
InsiderScore provides research and analytics covering these important ownership datasets. Company Scores quantify insider sentiment at each company. 10B5-1 Monitor analyzes pre-planned selling levels. Insider histories and profitability ratings. 30,000 quarterly updates and plan revisions. Monitor management follow-through and tendencies. 25 trillion in buybacks including impact on shares outstanding. Put, Call and Debt positions in quarterly 13F coverage.
Insiders Corner by Michael Brush at Investorideas. Thursday, February 15, 2007. Cancer Drug IPO Sees Strong Insider Interest. The company has two potential drugs moving into late-stage clinical trials, plus two in preclinical studies, and another in very early-stage development.